Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | PPIA | P62937 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30885335 | 1.00 | OPRL1 (0.33) | OPRL1OPRD1NPSR1OPRM1PPIA | |
| SCHEMBL26893877 | 1.00 | OPRL1 (0.33) | OPRL1OPRD1NPSR1OPRM1PPIA | |
| SCHEMBL29940079 | 1.00 | OPRL1 (0.33) | OPRL1OPRD1NPSR1OPRM1PPIA | |
| SCHEMBL29940065 | 1.00 | OPRL1 (0.33) | OPRL1OPRD1NPSR1OPRM1PPIA | |
| SCHEMBL29851149 | 0.93 | NPSR1 (0.31) | NPSR1 | |
| SCHEMBL24649055 | 0.93 | NPSR1 (0.31) | NPSR1 | |
| SCHEMBL26893933 | 0.84 | OPRL1 (0.33) | OPRL1OPRD1NPSR1OPRM1PPIA | |
| SCHEMBL31442177 | 0.84 | OPRL1 (0.33) | OPRL1OPRD1NPSR1OPRM1PPIA | |
| SCHEMBL30922808 | 0.84 | OPRL1 (0.33) | OPRL1OPRD1NPSR1OPRM1PPIA | |
| SCHEMBL30709846 | 0.83 | TSHR (0.32) | NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059205-A1 | Heterocyclic Compounds and Methods of Use | AMGEN INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-20250059179-A1 | Heterocyclic Compounds and Methods of Use | AMGEN INC. (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4329888-A1 | 2-AMINOBENZOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | Amgen Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| EP-4087573-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
| WO-2022232332-A1 | 2-AMINOBENZOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2022127827-A1 | KRASG12C PROTEIN MUTATION INHIBITOR AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | 上海维申医药有限公司 | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250059179-A1 | Heterocyclic Compounds and Methods of Use | KRAS, NRAS, HRAS | OPRL1 4567/4885OPRD1 2932/4885NPSR1 4800/4885 |
| US-20250059205-A1 | Heterocyclic Compounds and Methods of Use | KRAS, NRAS, HRAS | OPRL1 4567/4885OPRD1 2932/4885NPSR1 4800/4885 |
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | OPRL1 4628/4885OPRD1 4708/4885NPSR1 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.